Introduction {#Sec1}
============

The coupling of the increased percentage of elderly in the world's population and the incidences of chronic diseases is stimulating renewed interest in understanding the role of genetics, environmental factors, and their interactions with individual susceptibility to disease \[[@CR1]\]. However, the determination of nutritional requirements for optimizing metabolism for an individual or population remains challenging due to the complexity of food macro- and micronutrient composition, intersubject variability in physiological responses, environmental, and genetic factors \[[@CR2]\]. Over the last two decades, the era of omics technologies has provided an innovative paradigm for exploring physiological and pathological processes through broad and deep biological phenotyping \[[@CR3]\]. The methionine cycle is among the many central pathways that contribute to human health. Dysfunction of this pathway has been linked to cardiovascular disease, mild cognitive decline, vascular dementia, and Alzheimer's disease \[[@CR4]\]. In addition, co-factors derived from diet are crucial for proper functioning of the methionine cycle. A key product of this pathway, *S*-adenosylmethionine (SAM), is itself a co-factor and substrate for methylation of DNA, protein, and RNA as well as biosynthetic reactions of key brain metabolites \[[@CR5]\]. Hence, optimizing this pathway through nutrition may protect the brain from damage and reduce the risk of cardiovascular events. Monitoring the activity of this pathway in response to nutrition through metabolomics analysis (i.e., nutritional metabolomics) would generate a more comprehensive understanding of the interplay between host, environment, and nutrient interactions \[[@CR6]\]. In particular, mass spectrometry (MS)-based metabolomics methods have demonstrated robust, accurate, and precise quantitation of several homocysteine--methionine cycle biomarkers in diverse biological matrices \[[@CR7]--[@CR10]\]. However, no single and high-throughput method currently exists to monitor both metabolites and co-factors in the methionine pathway. Most available analytical methods for methionine pathway metabolites have so far deployed multiple and typically separate chromatographic, derivatization, and/or detection schemes to identify and quantify methionine, sulfur-containing amino acids, homocysteine (HCy) and cysteine, *S*-adenosylmethionine/*S*-adenosylhomocysteine (SAM/SAH), and B vitamins \[[@CR11]--[@CR15]\]. To address this limitation, we have recently developed a new method for the simultaneous quantitation of 13 metabolites and co-factors from the so-called methionine pathway by liquid chromatography--tandem mass spectrometry (LC--MS/MS) in red blood cells \[[@CR16]\]. In the present contribution, we introduce a further development of the method to enable a highly accurate and precise quantitation of 17 metabolites in plasma, including homocysteic acid (HA), taurine, serine, cysteine, glycine, homocysteine, riboflavin, methionine, pyridoxine, cystathionine, pyridoxamine, SAH, SAM, betaine, choline, dimethylglycine (DMG), and 5-methyltetrahydrofolic acid (5-MTHF) (Fig. [1](#Fig1){ref-type="fig"}). This improved method is also based on a simple sample preparation, which combined to a short chromatographic run time ensures a high sample throughput. This novel analytical strategy was also successfully applied for cerebrospinal fluid (CSF) analysis. Thus, this method provides a novel metabolomics approach for large-scale observational and human intervention studies. We demonstrate its applicability by analyzing plasma and CSF samples from healthy elderly subjects and patients diagnosed with Alzheimer's disease (AD).Fig. 1Metabolic pathway involving the measured (*blue*) metabolites from the homocysteine--methionine cycle

Materials and methods {#Sec2}
=====================

Materials {#FPar1}
---------

LC--MS-grade acetonitrile (ACN), LC-grade methanol (MeOH), formic acid, perfluoroheptanoic acid (PFHA), ascorbic acid, sodium hydroxide (NaOH) 0.1 M, hydrochloric acid (HCl), tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT), and ammonium acetate (NH~4~OAc) were purchased from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). Deionized water (*R* \> 18 ΩM/cm, TOC \< 10 ppb) was used throughout the experiments and produced by a Millipore-Q water system (Millipore, Bedford, MA, USA).

HA, taurine, serine, cystine, glycine, homocystine (HCy2), riboflavin, methionine, pyridoxine, cystathionine, SAH, pyridoxamine, SAM, DMG, choline, betaine, 5-MTHF, taurine-^13^C~2~, glycine-d~2~, riboflavin-dioxopyrimidine-^13^C~4~ ^15^N~2~, and methionine-d~3~ standards were purchased from Sigma-Aldrich Chemie GmbH.

HA-d~4~, serine-d~3~, pyridoxine-d~2~, cystathionine-d~4~, SAM-d~4~, DMG-d~6~, choline-d~9~, and betaine-d~11~ were purchased from CDN Isotopes (Pointe-Claire, Quebec, Canada). Cystine-d~4~, homocystine-d~8~, and pyridoxamine-d~3~ were purchased from Cambridge Isotopes Laboratories (Andover, MA, USA). SAH-d~4~ was purchased from Cayman Chemical (Ann Arbor, MI, USA). 5-MTHF-^13^C~5~ was purchased from Merck (Schaffhausen, Switzerland).

Preparation of the individual standard and internal standard solutions {#FPar2}
----------------------------------------------------------------------

Standard solutions were prepared individually in 0.1 M HCl (or in 10 mmol/L NH~4~OAc, 0.1 M NaOH, or in a mixture of MeOH/H~2~O depending on their solubility). Only 5-MTHF was dissolved in a mixture of 10 mmol/L NH4OAc with 10 % ascorbic acid and 2 % DTT in H~2~O to prevent oxidation. The same dilution solvents were used for individual internal standard (IS) stock solutions (Table [S1](#MOESM1){ref-type="media"}, see Electronic Supplementary Material (ESM)). Standard and IS solutions were stored at −20 °C for up to 3 months.

Calibration curves and QC samples {#FPar3}
---------------------------------

Calibration standards were prepared by dilution of standard stock solutions in ACN/H~2~O (5/95; *v*/*v*) to obtain seven calibration solutions (calibrants 1 to 7) in micromolar range for HA, taurine, serine, cystine, glycine, methionine, HCy2, DMG, betaine, and choline and in nanomolar range for riboflavin, pyridoxine, cystathionine, pyridoxamine, SAH, SAM, and 5-MTHF as described in Table [S2](#MOESM1){ref-type="media"} (see ESM). An IS working solution was prepared by dilution of IS standard stock solutions in ACN/H~2~O (5/95; *v*/*v*) (see ESM Table [S3](#MOESM1){ref-type="media"}) and stored at −20 °C for up to 3 months. Calibration samples were prepared with each batch of samples and injected at both the beginning and the end of the sample sequence. Fifty microliters of each calibration solution was pipetted and transferred into a 1.5-mL microcentrifuge tube. A volume of 10 microliters of IS working solution was then added to these solutions. Fifty microliters of TCEP (100 mg/mL) and then 140 μL of ACN/H~2~O (5/95; *v*/*v*) solution were furtherly added to the mixture. The tubes were placed on an autosampler rack and vortexed on a plate vortexer for 15 min at 1350 rpm. The solutions were transferred into vials and ready for LC--MS/MS analysis. Quality controls (QCs) at two different concentrations were added to each batch of samples. The low QC (at the same concentration as calibration level 3) and high QC (calibration level 6) samples were prepared using the same protocol as the calibration samples.

LC--MS/MS instrumentation {#FPar4}
-------------------------

The instrumental methodology was previously reported for red blood cell analysis \[[@CR16]\] and is fully described in the ESM (Table [S4](#MOESM1){ref-type="media"} and Table [S5](#MOESM1){ref-type="media"}). Briefly, a high-throughput method was developed using LC--MS/MS. Separation and analysis were performed on an Accela UHPLC 1250 Pump (Thermo Fisher Scientific Inc., Waltham, MA, USA) coupled to a TSQ Quantum Vantage triple quadrupole (Thermo Fisher Scientific Inc., Waltham, MA, USA) equipped with a heated electrospray ionization (H-ESI) source. Chromatographic separation was obtained using gradient elution on a reversed-phase UPLC XSelect HSST3 2.5 μm, 100 × 2.1 mm I.D. column (Waters Corporation, Milford, MA, USA). The injection volume was 10 μL and the total run time of analysis was 13 min.

Human sample collection for method validation {#FPar5}
---------------------------------------------

The human sub-cohort was supplied from PrecisionMed, Inc. (CA, USA, protocol 8009). This sub-cohort comprises 12 individuals: 6 control subjects and 6 patients diagnosed with Alzheimer's disease (AD). All the subjects are aged 50 years and older.

Plasma and CSF sample collection and processing {#FPar6}
-----------------------------------------------

Plasma or CSF frozen samples were thawed and vortexed for 10 s. A 50-μL volume of plasma or CSF samples was transferred by pipetting into a 1.5-mL microcentrifuge tube. Ten microliters of IS solution was added to plasma or CSF samples. Fifty microliters of TCEP solution and then 140 μL of methanol + 1 % FA were then added to the mixture. The tubes were placed in a multitube vortexer for 15 min at 1350 rpm at 4 °C and centrifuged at 14,500 rpm for 5 min. The supernatants were pipetted and filtered through a 0.22-μm filter and placed into vials for LC--MS/MS analysis.

Matrix effects {#FPar7}
--------------

Matrix effects were assessed by considering the post-extraction IS analyte spiking. Two sets of samples (five replicates for each set) were used: one containing the IS analyte added to an extracted matrix (post-extraction sample) and the other containing the IS analyte in the mobile phase solvent. Both sets of samples were spiked with the same concentration of IS analyte. Matrix effect values in percent were calculated using the following equation: matrix effect (%) = *B*/*A* \* 100 (*A* = mean of external solution peak area, *B* = post-extraction sample peak area).

Validation procedure {#FPar8}
--------------------

The validation procedure involves the following criteria: specificity and selectivity, limit of detection (LOD) and limit of quantitation (LOQ), linearity, trueness, precision (repeatability and intermediate precision), and recovery. Specificity and selectivity were assessed using the retention time and mass spectrum profile of pure standards and compared to the ones in unspiked CSF and plasma samples.

LOD and LOQ were evaluated based on the signal-to-noise ratio (*S*/*N*), at least above 3 for the LOD and 10 for the LOQ by injecting spiked plasma or CSF samples with the IS mixture of all analytes.

The calibration curves were constructed, at each concentration level, by calculating the chromatographic peak area ratio of the analyte and its IS for each metabolite.

Trueness and precision (repeatability and intermediate precision) were assessed by spiking plasma and CSF samples at low, medium, and high levels in six replicates for each level. For repeatability, six replicates were performed by the same operator on three separate occasions in a short period of time (less than 1 month). For intermediate precision, the same protocol was followed with additional analyses being carried out by two other individuals on a total of six separated occasions.

Statistical analysis {#FPar9}
--------------------

Two-sample Kolmogorov--Smirnov (KS) tests were used to determine the statistical significance between gender distributions of metabolites. Uncorrected *P* values less than 0.05 were considered significant. The statistical software R v.3.2.2 \[[@CR17]\] was used as a general platform for such analyses, and the package ggplot2 \[[@CR18]\] was used for visualization.

Results and discussion {#Sec3}
======================

The analytical method analyzes 17 metabolites involved in the homocysteine--methionine cycle. The previously described instrumental methodology used for the RBC matrix \[[@CR16]\] was applied to the analysis of plasma and CSF samples. The analytical method extends the metabolite coverage, which now also includes betaine, DMG, choline, and 5-MTHF acid. Such an approach enables a more comprehensive assessment of homocysteine contribution via methionine synthase but also through betaine homocysteine methyltransferase (BHMT) to the methionine metabolism. The BHMT pathway is particularly active in both liver and kidney, which are the main organs for storage of large amounts of betaine \[[@CR19]\]. This metabolite is actually distributed widely in plants and animals, particularly in seafood, and an inadequate dietary intake leads to hypomethylation of proteins, RNA, and DNA. Inadequate levels of betaine lead to disturbed hepatic protein metabolism, expressed by elevated homocysteine concentrations and decreased SAM concentrations in plasma \[[@CR20]\]. Less well known are the correlations between betaine availability in plasma and its concentration in the CSF. Changes in the methionine cycle may be monitored by betaine--DMG conversion and the variations in 5-MTHF concentrations in plasma. In addition to betaine, choline is another important dietary methyl group donor particularly during folate deficiency \[[@CR21]\]. Choline may enter the homocysteine--methionine cycle through its oxidation to betaine which is used as a substrate in the BHMT reaction that links choline and betaine to the folate-dependent methionine pathway. Our analytical method combines LC with MS/MS which provides a high specificity and sensitivity, as well as a fast run time (13 min). Compared to our previous methodology for RBC analysis, the current workflow for plasma and CSF does not require the same sample preparation, since there is no metabolite extraction from cells. Sample treatment was optimized for plasma samples and then applied to CSF samples. A simple and quick sample preparation including protein precipitation and chemical reduction was required for total cysteine and total homocysteine quantitation.

Extraction method development {#FPar10}
-----------------------------

Homocysteine is found primarily in plasma in the form of free homocysteine (HCy), dimers, and analogue molecular forms bound by disulfide bridges to proteins or other thiol-containing compounds. The presence of these multiple forms complicates the development of reliable analytical methods. One common approach consists in the chemical reduction of all disulfide bonds to provide a total homocysteine measurement. Total homocysteine is therefore the sum of all homocysteine obtained from the reduction of these disulfide bonds; this also applies to total cysteine. Two reducing agents are frequently used for the reduction of disulfide bounds: DTT \[[@CR22]--[@CR26]\] and TCEP \[[@CR27], [@CR28]\]. We assessed both reducing agents and found that TCEP performed best in terms of stability and extraction efficiency. Indeed, TCEP provides a rapid chemical reduction of disulfide bonds at room temperature without any pH adjustments \[[@CR29]\]. Yet, a concentration of 200 mM TCEP was found not sufficient to totally reduce the disulfide bonds, and the concentration was increased to 100 mg/mL \[[@CR30]\]. Common solvents such as MeOH and ACN \[[@CR31]\] are reported for protein precipitation for the analysis of total homocysteine in blood with or without the addition of acids such as FA. We found that MeOH + 1 % FA gave on overall the best mass spectral peak intensities and shapes.

Chromatography and mass spectra {#FPar11}
-------------------------------

The chromatographic method optimization is fully described in our previously published paper \[[@CR16]\]. In this method, retention of the most polar compounds on a reversed-phase column was not possible without the use of ion-pairing agents. Typical chromatograms of a spiked CSF sample at the medium level are shown in Fig. [2](#Fig2){ref-type="fig"}. Optimal selected reaction monitoring (SRM) conditions were obtained in positive electrospray ionization mode and are reported in Table [1](#Tab1){ref-type="table"}.Fig. 2Typical SRM chromatograms obtained for spiked CSF samples at the medium level Table 1Single reaction monitoring (SRM) transitionsAnalyteRT^a^ (min)SRM transitions (*m*/*z*)CE (eV)Glycine1.476 → 3011Glycine-d~2~1.478 → 327Serine1.15106 → 6010Serine-d~3~1.15109 → 6311Cysteine1.4122 → 5920Cysteine-d~2~1.4124 → 6123Taurine0.6126 → 10811Taurine-^13^C~2~0.6128 → 11011Homocysteine2.85136 → 9010Homocysteine-d~4~2.85140 → 9410Methionine4.3150 → 10410Methionine-d~3~4.3153 → 1079Pyridoxine4.5170 → 13418Pyridoxine-d~2~4.5172 → 13619Pyridoxamine5.75169 → 15211Pyridoxamine-d~3~5.75172 → 15512Homocysteic acid0.6184 → 13810Homocysteic acid-d~4~0.6188 → 1429Cystathionine5.2223 → 13413Cystathionine-d~4~5.2227 → 13813Riboflavin3.4377 → 24315Riboflavin-^13^C~4~ ^15^N~2~3.4383 → 24913SAH5.6385 → 13421SAH-d~4~5.6389 → 13618SAM5.9399 → 25014SAM-d~3~5.9402 → 25013DMG1.25104 → 5812DMG-d~6~1.25110 → 6415Betaine1.4118 → 5825Betaine-d~11~1.4129 → 6631Choline4.35104 → 6017Choline-d~9~4.35113 → 69195-MTHF4.9460 → 313155-MTHF-^13^C~5~4.9465 → 31326^a^RT retention time given as information only

Validation procedures. Estimated LOD and LOQ {#FPar12}
--------------------------------------------

Due to endogenous levels of some analytes and incomplete reference material for all the analyzed metabolites, the LOD and LOQ were estimated by injecting plasma and CSF samples spiked by serial dilution of IS solution until reaching a *S*/*N* above 3 for the LOD and above 10 for the LOQ. Stable isotope-labeled compounds have the same physico-chemical properties and should therefore have the same analytical behavior as the analogue molecules (e.g., retention time, intensity). Estimated LOD and LOQ values from plasma and CSF samples spiked with IS solutions are reported in Table [2](#Tab2){ref-type="table"}.Table 2Estimated limits of detection (LOD) and limits of quantitation (LOQ) values from plasma and CSF samples spiked with labeled internal standard (IS) solutionsAnalyteIn plasmaIn CSFLODLOQUnitsLODLOQUnitsHomocysteic acid0.51.0μM0.250.5μMTaurine2.03.0μM4.05.0μMSerine2.03.0μM0.51.0μMTotal cysteine0.10.5μM0.050.125μMGlycine2.03.0μM1.02.0μMTotal homocysteine1.02.0μM0.1250.25μMRiboflavin1.02.0nM4.05.0nMMethionine2.03.0μM0.51.0μMPyridoxine2.03.0nM1.52.0nMCystathionine0.51.0nM0.51.0nMSAH0.10.5nM2.04.0nMPyridoxamine2.03.0nM0.250.5nMSAM2.03.0nM2.04.0nMDMG2.04.0μM0.10.4μMBetaine0.050.125μM0.010.02μMCholine0.020.05μM0.050.1μM5-MTHF6.08.0nM2.04.0nM

Linearity of the calibration {#FPar13}
----------------------------

We assessed whether to use solvent-based calibration curves or matrix-matched external calibration curves to accurately quantitate our 17 metabolites. Calibration curves were therefore performed in both solvent and sample matrix (plasma and CSF) using 7 calibration levels. The plasma or CSF calibration slopes differed by less than 16 % from the solvent-based calibration curves. Without IS correction, these differences would have been far higher in such complex matrices. These results show the importance of using isotopically labeled compounds as spiked IS to efficiently compensate for the matrix effect. For simplicity, only water-based calibration curves were used during this validation to accurately quantify these analytes in plasma or CSF samples.

The linearity of the calibration curves was assessed using seven calibration levels with five replicates each. The relationship between analyte response and concentration was linear in the solvent in the range mentioned in Table [S2](#MOESM1){ref-type="media"} (see ESM). For all compounds including the additional compounds, i.e., DMG, betaine, choline, and 5-MTHF, a linear regression model was used. A weighting factor of 1/*x* was applied for all compounds to achieve a linear model with the lowest relative errors at each level. All coefficients of determination (*r* ^2^) were found above 0.99. The acceptance criterion for each back-calculated standard concentration was ±15 % deviation from the nominal value except at the lowest level, i.e., level 1, which was set at ±20 %. All values were found within these ranges with a maximum of 2 excluded calibration points per curve.

Trueness, precision, and recovery {#FPar14}
---------------------------------

Values for trueness and precision are summarized in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. For plasma samples, within-run precision (repeatability *r*) and between-run precision (intermediate reproducibility iR) CV values were found below 20 % for the lowest spiking level and below 15 % for the medium and high spiking levels, which are within the recommended limits \[[@CR32]\]. For CSF samples, *r* and iR values were found below 16 % for the lowest spiking level and below 12 % for the medium and high spiking levels. Recoveries were found between 90 and 108 % for plasma samples and between 96 and 109 % for CSF samples, which are also within the recommended limits.Table 3Repeatability and intermediate trueness and precision values at three different concentration levels (*n* = 6 per day, per level) to determine accuracy of the developed method in plasma samplesAnalyteTargeted concentrationMean ± SDUnitsRecovery ± RSD (%)CV~*r*~ (%)CV~iR~ (%)Homocysteic acid15.015.0 ± 0.8μM100.2 ± 2.16.27.7100.0102.2 ± 3.9102.2 ± 1.66.67.2200.0199.6 ± 7.399.8 ± 1.56.36.8Taurine30.029.6 ± 2.8μM98.6 ± 3.812.514.7200.0188.0 ± 14.394.0 ± 3.17.310.1400.0370.0 ± 24.092.5 ± 4.85.78.3Serine30.030.1 ± 0.8μM100.3 ± 1.17.97.7200.0203.4 ± 6.2101.7 ± 1.23.24.3400.0405.6 ± 11.6101.4 ± 1.24.14.7Total cysteine15.016.1 ± 0.9μM107.6 ± 4.114.114.0100.0101.5 ± 1.9101.5 ± 0.87.97.5200.0191.4 ± 12.595.7 ± 2.77.19.2Glycine30.028.6 ± 1.8μM95.3 ± 2.615.215.2200.0197.9 ± 6.199.0 ± 1.35.15.6400.0399.9 ± 15.8100.0 ± 1.64.85.9Total homocysteine15.014.6 ± 0.4μM97.5 ± 1.02.93.7100.0100.3 ± 1.7100.3 ± 0.72.22.6200.0197.0 ± 5.098.5 ± 1.06.26.2Riboflavin30.029.5 ± 3.1nM98.3 ± 4.318.019.5200.0193.9 ± 10.297.0 ± 2.16.27.7400.0399.5 ± 28.099.9 ± 2.98.610.5Methionine15.015.2 ± 0.4μM101.4 ± 1.16.16.2100.0103.1 ± 2.4103.1 ± 1.82.83.5200.0202.7 ± 5.9101.4 ± 1.23.64.4Pyridoxine15.014.4 ± 0.4nM96.0 ± 2.49.18.8100.0100.8 ± 3.2100.8 ± 1.34.04.8200.0194.8 ± 9.397.4 ± 1.95.26.7Cystathionine30.030.8 ± 1.9nM102.5 ± 2.517.216.8200.0194.7 ± 16.897.3 ± 3.59.712.4400.0388.3 ± 26.597.1 ± 2.88.610.4SAH30.030.8 ± 3.1nM102.6 ± 4.117.919.1200.0202.2 ± 11.2101.1 ± 2.312.712.8400.0398.8 ± 25.099.7 ± 2.611.712.4Pyridoxamine15.013.5 ± 1.0nM90.3 ± 6.216.016.4100.098.5 ± 4.498.5 ± 1.87.58.2200.0195.1 ± 11.397.5 ± 2.49.510.4SAM30.026.5 ± 2.0nM88.4 ± 7.218.518.5200.0200.6 ± 10.0100.3 ± 2.012.112.1400.0415.9 ± 36.7104.0 ± 3.610.112.7DMG5.04.9 ± 0.1μM97.6 ± 1.45.25.140.039.5 ± 2.098.7 ± 2.13.96.280.079.5 ± 2.299.3 ± 1.12.43.6Betaine12.512.6 ± 0.9μM100.7 ± 2.97.09.5100.096.3 ± 2.396.3 ± 2.14.95.1200.0196.3 ± 5.098.1 ± 1.03.03.7Choline5.04.9 ± 0.2μM98.8 ± 1.35.35.840.039.4 ± 0.898.4 ± 0.84.24.380.079.4 ± 1.799.2 ± 0.91.42.55-MTHF50.047.8 ± 2.7nM95.7 ± 2.315.114.9400.0393.0 ± 26.598.3 ± 2.712.813.5800.0804.4 ± 26.8100.5 ± 1.410.510.2 Table 4Repeatability and intermediate trueness and precision values at three different concentration levels (*n* = 6 per day, per level) to determine accuracy of the developed method in CSF samplesAnalyteTargeted concentrationMean ± SDUnitsRecovery ± RSD (%)CV~*r*~ (%)CV~iR~ (%)Homocysteic acid12.512.9 ± 0.3μM103.2 ± 1.86.76.5100.0102.4 ± 4.2102.4 ± 1.74.86.0200.0200.7 ± 8.5100.4 ± 1.73.95.5Taurine25.025.4 ± 0.5μM101.7 ± 0.98.88.3200.0199.4 ± 10.699.7 ± 2.25.07.0400.0386.5 ± 16.796.6 ± 1.83.15.2Serine25.024.5 ± 1.1μM98.1 ± 1.76.57.3200.0202.6 ± 5.9101.3 ± 1.23.84.6400.0402.8 ± 14.3100.7 ± 1.42.74.3Total cysteine12.512.7 ± 0.4μM101.3 ± 1.44.75.4100.0102.8 ± 3.0102.7 ± 1.23.24.2200.0201.0 ± 4.9100.5 ± 1.02.73.5Glycine25.025.2 ± 1.3μM100.7 ± 2.15.37.0200.0201.7 ± 6.0100.8 ± 1.23.44.3400.0393.3 ± 8.398.3 ± 0.92.53.1Total homocysteine12.512.4 ± 0.6μM99.2 ± 1.92.65.3100.0102.7 ± 1.8102.7 ± 1.53.53.7200.0202.4 ± 4.4101.2 ± 0.92.22.9Riboflavin25.025.4 ± 2.8nM101.7 ± 4.51618.3200.0202.1 ± 7.8101.0 ± 1.611.711.4400.0402.5 ± 23.8100.6 ± 2.47.89.2Methionine12.512.9 ± 0.6μM103.0 ± 1.84.96.3100.0104.2 ± 4.2104.2 ± 1.63.45.1200.0203.9 ± 6.5102.0 ± 1.33.44.5Pyridoxine12.512.6 ± 0.3nM100.9 ± 0.96.66.4100.0102.3 ± 4.3102.3 ± 1.73.95.5200.0200.7 ± 6.8100.4 ± 1.43.34.5Cystathionine25.024.1 ± 1.0nM96.5 ± 1.611.411.1200.0213.9 ± 16.3107.0 ± 3.17.210.1400.0433.1 ± 28.4108.3 ± 4.77.19.2SAH50.048.1 ± 3.5nM96.3 ± 3.012.813.8400.0403.8 ± 14.3100.9 ± 1.46.97.2800.0773.0 ± 18.596.6 ± 2.06.96.7Pyridoxamine12.512.1 ± 0.4nM96.8 ± 2.09.99.5100.0101.3 ± 3.5101.3 ± 1.47.87.9200.0200.0 ± 8.8100.0 ± 1.87.68.2SAM50.051.1 ± 4.4nM102.1 ± 3.513.915.3400.0406.2 ± 19.1101.6 ± 1.98.59.1800.0807.2 ± 41.6100.9 ± 2.15.97.5DMG5.05.0 ± 0.2μM99.8 ± 1.23.14.140.040.6 ± 1.1101.5 ± 1.13.24.080.080.8 ± 2.1101.0 ± 1.02.83.6Betaine5.05.2 ± 0.2μM102.5 ± 1.55.26.140.041.1 ± 1.0102.8 ± 1.73.23.880.080.5 ± 2.6100.7 ± 1.32.33.8Choline5.05.0 ± 0.1μM100.2 ± 1.24.95.340.040.7 ± 1.0101.8 ± 1.03.13.880.079.9 ± 1.099.9 ± 0.52.93.05-MTHF50.049.5 ± 3.9nM99.1 ± 3.212.513.9400.0408.0 ± 7.7102.0 ± 0.85.75.5800.0818.2 ± 29.8102.3 ± 1.53.85.0

Matrix effects {#FPar15}
--------------

Matrix effects may occur in any LC--MS analysis because of the presence of co-eluting compounds in the sample matrix, especially in complex matrices such as plasma. The use of stable isotope-labeled related compounds as IS is a well-known efficient approach to overcome and correct matrix effects and therefore improve the method's accuracy \[[@CR33]\]. Although stable isotope-labeled compounds were used in our method, we still evaluated ion suppression and enhancement. Besides, ion suppression may still occur when using ion pairing such as heptafluorobutyric acid. Quantitative measurements for estimating the matrix effects are presented in Table [S6](#MOESM1){ref-type="media"} in the ESM.

Application to biological samples {#Sec4}
---------------------------------

The homocysteine--methionine cycle is of particular importance for cognitive function and Alzheimer's disease. For instance, an imbalance of this metabolic pathway, marked by hyperhomocysteinemia and/or an altered SAM/SAH ratio, is a hallmark of memory loss and cognitive decline in elderly populations \[[@CR34], [@CR35]\] This loss of metabolic homeostasis may result from deficiency in metabolites and co-factors---such as vitamin B~12~ or folic acid---directly and indirectly involved in the methylation of homocysteine. An increased interest exists to decipher their role as potential biomarkers of neurodegeneration in Alzheimer's disease \[[@CR36]--[@CR38]\]. The robustness of our method for the sensitive detection and quantitation of the 17 metabolites and co-factors of methionine metabolism was assessed in biological materials collected from healthy donors and patients diagnosed with Alzheimer's disease. We reported in Table [5](#Tab5){ref-type="table"} plasma and CSF concentrations for the 17 metabolites in control and AD subjects. In blood plasma and CSF, the AD patients showed a significantly higher concentration of SAH compared to healthy subjects, but a lower circulating concentration of SAM (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}), a feature that was reported previously by other authors in several larger clinical studies using different and complementary assays \[[@CR39]--[@CR41]\]. However, despite the lack of statistical significance, our analysis also showed a trend toward a higher plasma level of homocysteine in those affected patients. In addition, a significant increase in glycine concentration in CSF was observed in AD patients, an observation that was confirmed by a similar trend in plasma samples. This metabolic pattern has also been reported previously by other authors using a targeted analytical method for amino acids \[[@CR42]\]. Therefore, this application to real biological samples, although limited due to the number of subjects, demonstrated the importance of capturing sensitive metabolic readouts and contributed to obtain complete individual clinical phenotypes in plasma and CSF. Knowledge of the metabolites and co-factor distribution between plasma and CSF may yield information to better understand the impact of metabolic dysregulation and vitamin deficiencies/insufficiencies in the context of aging, cardiometabolic, and cognitive health research.Table 5Plasma and CSF concentrations of 17 metabolites in control and AD subjects (mean ± SD)AnalytePlasmaCSFUnitsControl (*n* = 6)AD (*n* = 6)Control (*n* = 6)AD (*n* = 6)Mean ± SDMean ± SDMean ± SDMean ± SDHomocysteic acid\<LOD\<LOD\<LOD\<LODμMTaurine81.5 ± 30.971.6 ± 1827.8 ± 4.724.0 ± 4.8μMSerine79.6 ± 15.785.8 ± 19.425.4 ± 4.832.9 ± 14.5μMTotal cysteine144.4 ± 9.9153.2 ± 32.91.1 ± 0.42.4 ± 2.2μMGlycine250.0 ± 112.1339.3 ± 180.67.8 ± 4.425.6 ± 20.3μMTotal homocysteine5.3 ± 1.68.1 ± 6.9\<LOQ\<LOQμMRiboflavin68.2 ± 66.621.9 ± 30.76.7 ± 5.312.9 ± 6.5nMMethionine16.9 ± 2.816.8 ± 3.43.7 ± 0.45.3 ± 1.6μMPyridoxine\<LOD\<LOD\<LOD\<LODnMCystathionine116.7 ± 34.2175.7 ± 112.346.0 ± 36.742.0 ± 32.9nMSAH25.7 ± 9.940.9 ± 9.814.3 ± 2.526.1 ± 9.4nMPyridoxamine\<LOD\<LOD\<LOD\<LODnMSAM88.5 ± 18.168.5 ± 19.4191.4 ± 31.1150.7 ± 30.2nMDMG\<LOQ\<LOQ\<LOQ\<LOQμMBetaine45.9 ± 14.545.8 ± 17.0\<LOD\<LODμMCholine11.2 ± 3.511.6 ± 3.73.0 ± 0.73.5 ± 0.5μM5-MTHF56.6 ± 23.3191.9 ± 363.560.9 ± 11.857.4 ± 18.8nM Fig. 3Plots in plasma samples. Concentrations for glycine and total homocysteine are in micromolars and for SAH and SAM in nanomolars. *P* values are reported Fig. 4Plots in CSF samples. Concentrations for glycine are in micromolars and for SAH and SAM in nanomolars. *P* values are reported

Conclusions {#Sec5}
===========

A precise evaluation of changes in the homocysteine--methionine pathway is key to understand the relation among diet, nutrition and metabolic requirements, and cardiometabolic or neurological disorders. Quantitation of elements of this pathway is often covered by several analytical methods that just cover it partially. To fill this analytical gap, we have developed a robust, high-throughput LC--MS/MS method for the quantitation of 17 key metabolites embedded into the homocysteine--methionine metabolism. The approach described here provides a novel analytical tool allowing scientists to capture in one single analysis changes in the homocysteine--methionine pathway and their co-factors in plasma and CSF samples. The proposed analytical method does this with a high level of accuracy and reproducibility, making it especially interesting for large epidemiologic studies.
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